ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel for Adults with Relapsed and Refractory Multiple Myeloma
September 23, 2020Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced the submission of their Biologics License Application (BLA) to the U.S. -
Breakthrough immunotherapy for Chronic Hepatitis B virus infection
August 09, 2017This study, a collaborative effort between Duke-NUS, various prestigious Singapore & German institutions and Lion TCR, provides a potential solution to control the HBV infection, potentially complete clearance of HBV virus and possibly leading to a cure f
Pharma Sources Insight January 2025
